{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T10:29:21Z","timestamp":1794479361946,"version":"4.9.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24ama121052"],"award-info":[{"award-number":["JP24ama121052"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22H05577"],"award-info":[{"award-number":["22H05577"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K08642"],"award-info":[{"award-number":["24K08642"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Government of Japan Ministry of Education Culture Sports Science and Technology","doi-asserted-by":"publisher","award":["22K15049"],"award-info":[{"award-number":["22K15049"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.biopha.2026.119432","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T19:21:29Z","timestamp":1777317689000},"page":"119432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Combination therapy with clinically approved PPAR\u03b1\/\u03b4\/\u03b3 subtype-selective agonists pemafibrate, seladelpar, and pioglitazone in a 4-week diet-induced early-stage MASLD mouse model"],"prefix":"10.1016","volume":"199","author":[{"given":"Akihiro","family":"Honda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shotaro","family":"Kamata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reina","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Minomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Ino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waka","family":"Kamichatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako","family":"Hishiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Akahoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9500-8889","authenticated-orcid":false,"given":"Shinsaku","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuto","family":"Nunomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bangzhong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5367-205X","authenticated-orcid":false,"given":"Isao","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119432_bib1","unstructured":"Global fatty liver day, British Liver Trust, \u3008https:\/\/britishlivertrust.org.uk\/global-fatty-liver-day\/\u3009, 2025 (accessed 26 December 2025)."},{"issue":"6","key":"10.1016\/j.biopha.2026.119432_bib2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41575-020-00408-y","article-title":"Therapeutic pipeline in nonalcoholic steatohepatitis","volume":"18","author":"Vuppalanchi","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"8","key":"10.1016\/j.biopha.2026.119432_bib3","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.bbalip.2007.01.007","article-title":"Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators","volume":"1771","author":"Zoete","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"issue":"3","key":"10.1016\/j.biopha.2026.119432_bib4","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1172\/JCI27989","article-title":"Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis","volume":"116","author":"Lefebvre","year":"2006","journal-title":"J. Clin. Invest"},{"issue":"5","key":"10.1016\/j.biopha.2026.119432_bib5","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nm.3159","article-title":"PPAR\u03b3 signaling and metabolism: the good, the bad and the future","volume":"19","author":"Ahmadian","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2026.119432_bib6","doi-asserted-by":"crossref","DOI":"10.1621\/nrs.13001","article-title":"Integrative and systemic approaches for evaluating PPAR\u03b2\/\u03b4 (PPARD) function","volume":"13","author":"Attianese","year":"2015","journal-title":"Nucl. Recept. Signal"},{"issue":"5","key":"10.1016\/j.biopha.2026.119432_bib7","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4239\/wjd.v7.i5.74","article-title":"Use of fibrates in the metabolic syndrome: A review","volume":"7","author":"Shipman","year":"2016","journal-title":"World J. Diabetes"},{"issue":"1","key":"10.1016\/j.biopha.2026.119432_bib8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11883-020-0823-5","article-title":"Pemafibrate, a New Selective PPAR\u03b1 Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases","volume":"22","author":"Yamashita","year":"2020","journal-title":"Curr. Atheroscler. Rep."},{"issue":"11","key":"10.1016\/j.biopha.2026.119432_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101727","article-title":"PPAR\u03b1 Ligand-Binding Domain Structures with Endogenous Fatty Acids and Fibrates","volume":"23","author":"Kamata","year":"2020","journal-title":"iScience"},{"issue":"12","key":"10.1016\/j.biopha.2026.119432_bib10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11892-019-1270-y","article-title":"Thiazolidinediones: the Forgotten Diabetes Medications","volume":"19","author":"Lebovitz","year":"2019","journal-title":"Curr. Diab. Rep."},{"issue":"20","key":"10.1016\/j.biopha.2026.119432_bib11","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.3390\/ijms20205055","article-title":"Exploration and development of PPAR modulators in health and disease: an update of clinical evidence","volume":"20","author":"Cheng","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119432_bib12","unstructured":"Novel Drug Approvals for 2024, US Food and Drug Adminisrration, \u3008https:\/\/www.fda.gov\/drugs\/novel-drug-approvals-fda\/novel-drug-approvals-2024\u3009, 2025 (accessed 26 December 2025)."},{"issue":"2","key":"10.1016\/j.biopha.2026.119432_bib13","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jhep.2018.03.011","article-title":"A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer","volume":"69","author":"Tsuchida","year":"2018","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119432_bib14","doi-asserted-by":"crossref","first-page":"G508","DOI":"10.1152\/ajpgi.00139.2019","article-title":"Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis","volume":"317","author":"Duparc","year":"2019","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119432_bib15","first-page":"813","article-title":"Characterization of diet based nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis in rodent models: Histological and biochemical outcomes","volume":"37","author":"Akbari","year":"2022","journal-title":"Histol. Histopathol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119432_bib16","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/cts.12735","article-title":"A 3-week nonalcoholic steatohepatitis mouse model shows elafibranor benefits on hepatic inflammation and cell death","volume":"13","author":"Briand","year":"2020","journal-title":"Clin. Transl. Sci."},{"issue":"8","key":"10.1016\/j.biopha.2026.119432_bib17","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.3390\/biom13081264","article-title":"Current clinical trial status and future prospects of PPAR-targeted drugs for treating nonalcoholic fatty liver disease","volume":"13","author":"Kamata","year":"2023","journal-title":"Biomolecules"},{"issue":"8","key":"10.1016\/j.biopha.2026.119432_bib18","doi-asserted-by":"crossref","first-page":"754","DOI":"10.5551\/jat.28720","article-title":"Transcriptome Analysis of K-877 (a Novel Selective PPAR\u03b1 Modulator (SPPARM\u03b1))-Regulated Genes in Primary Human Hepatocytes and the Mouse Liver","volume":"22","author":"Raza-Iqbal","year":"2015","journal-title":"J. Atheroscler. Thromb."},{"issue":"7","key":"10.1016\/j.biopha.2026.119432_bib19","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.3390\/biomedicines10071667","article-title":"Clinically Relevant Dose of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor \u03b1 Modulator (SPPARM\u03b1), Lowers Serum Triglyceride Levels by Targeting Hepatic PPAR\u03b1 in Mice","volume":"10","author":"Zhang","year":"2022","journal-title":"Biomedicines"},{"issue":"7","key":"10.1016\/j.biopha.2026.119432_bib20","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/hep4.1072","article-title":"The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice","volume":"1","author":"Haczeyni","year":"2017","journal-title":"Hepatol. Commun."},{"issue":"PtB","key":"10.1016\/j.biopha.2026.119432_bib21","article-title":"Therapeutic efficacy of mitochondria-targeted esculetin in the improvement of NAFLD-NASH via modulating AMPK-SIRT1 axis","volume":"124","author":"Singuru","year":"2023","journal-title":"Int. Immunopharmacol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119432_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23094726","article-title":"Functional and Structural Insights into Human PPAR\u03b1\/\u03b4\/\u03b3 Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate","volume":"23","author":"Honda","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.biopha.2026.119432_bib23","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.3390\/antiox12081523","article-title":"Functional and Structural Insights into the Human PPAR\u03b1\/\u03b4\/\u03b3 Targeting Preferences of Anti-NASH Investigational Drugs, Lanifibranor, Seladelpar, and Elafibranor","volume":"12","author":"Kamata","year":"2023","journal-title":"Antioxidants"},{"issue":"1","key":"10.1016\/j.biopha.2026.119432_bib24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/hep.32105","article-title":"YAP-TEAD mediates PPAR \u03b1-induced hepatomegaly and liver regeneration in mice","volume":"75","author":"Fan","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2026.119432_bib25","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/612089","article-title":"Peroxisome proliferator-activated receptor alpha target genes","volume":"2010","author":"Rakhshandehroo","year":"2010","journal-title":"PPAR Res"},{"issue":"9","key":"10.1016\/j.biopha.2026.119432_bib26","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/2211-5463.12497","article-title":"2D DIGE proteomic analysis reveals fasting-induced protein remodeling through organ-specific transcription factor(s) in mice","volume":"8","author":"Kamata","year":"2018","journal-title":"FEBS Open bio"},{"issue":"1","key":"10.1016\/j.biopha.2026.119432_bib27","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3390\/ijms24010264","article-title":"Peripheral Inflammatory Markers TNF-\u03b1 and CCL2 Revisited: Association with Parkinson's Disease Severity","volume":"24","author":"Xiromerisiou","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119432_bib28","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/s42003-024-06357-5","article-title":"Egr2 drives the differentiation of Ly6Chi monocytes into fibrosis-promoting macrophages in metabolic dysfunction-associated steatohepatitis in mice","volume":"7","author":"Iwata","year":"2024","journal-title":"Commun. Biol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119432_bib29","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00216-018-1506-8","article-title":"Mapping the triglyceride distribution in NAFLD human liver by MALDI imaging mass spectrometry reveals molecular differences in micro and macro steatosis","volume":"411","author":"Alamri","year":"2019","journal-title":"Anal. Bioanal. Chem."},{"issue":"44","key":"10.1016\/j.biopha.2026.119432_bib30","doi-asserted-by":"crossref","first-page":"42774","DOI":"10.1074\/jbc.M306022200","article-title":"Cholesterol and cholate components of an atherogenic diet induce distinct stages of hepatic inflammatory gene expression","volume":"278","author":"Vergnes","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"16","key":"10.1016\/j.biopha.2026.119432_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23169268","article-title":"Dietary Cholic Acid Exacerbates Liver Fibrosis in NASH Model of Sprague-Dawley Rats Fed a High-Fat and High-Cholesterol Diet","volume":"23","author":"Ichimura-Shimizu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2026.119432_bib32","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0939-6411(98)00033-2","article-title":"Characterization of an inclusion complex of cholesterol and hydroxypropyl-beta-cyclodextrin","volume":"46","author":"Williams","year":"1998","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"7075","key":"10.1016\/j.biopha.2026.119432_bib33","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nature04330","article-title":"Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation","volume":"439","author":"Watanabe","year":"2006","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.biopha.2026.119432_bib34","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1053\/j.gastro.2022.06.023","article-title":"AGA clinical practice update: diagnosis and management of nonalcoholic fatty liver disease in lean individuals: expert review","volume":"163","author":"Long","year":"2022","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.biopha.2026.119432_bib35","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/00365520802588133","article-title":"Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol","volume":"44","author":"Yasutake","year":"2009","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.biopha.2026.119432_bib36","unstructured":"Parmodia Tablets 0.1 mg interview form (in Japanese), \u3008https:\/\/www.info.pmda.go.jp\/go\/interview\/1\/270072_2183007F1025_1_015_1F.pdf\u3009, 2024 (accessed 26 December 2025)."},{"issue":"10","key":"10.1016\/j.biopha.2026.119432_bib37","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/apt.16596","article-title":"Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), versus placebo in patients with non-alcoholic fatty liver disease","volume":"54","author":"Nakajima","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2026.119432_bib38","unstructured":"LIVDELZI\u00ae (seladelpar) capsules, for oral use, US Food and Drug Administeration, \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/217899s000lbl.pdf\u3009, 2024 (accessed 26 December 2025)."},{"key":"10.1016\/j.biopha.2026.119432_bib39","doi-asserted-by":"crossref","first-page":"i1541","DOI":"10.1136\/bmj.i1541","article-title":"Pioglitazone use and risk of bladder cancer: population based cohort study","author":"Tuccori","year":"2016","journal-title":"Bmj 352"},{"key":"10.1016\/j.biopha.2026.119432_bib40","unstructured":"The Top 300 of 2023, ClinCalc.com, (2025), \u3008https:\/\/clincalc.com\/DrugStats\/Top300Drugs.aspx\u3009, 2025 (accessed 26 December 2025)."},{"key":"10.1016\/j.biopha.2026.119432_bib41","unstructured":"ACTOS Tablets 15\/30 interview form (in Japanese), \u3008https:\/\/pins.japic.or.jp\/pdf\/medical_interview\/IF00004434.pdf\u3009, 2025 (accessed 26 December 2025)."},{"issue":"5","key":"10.1016\/j.biopha.2026.119432_bib42","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.biopha.2026.119432_bib43","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"issue":"24","key":"10.1016\/j.biopha.2026.119432_bib44","doi-asserted-by":"crossref","first-page":"12020","DOI":"10.3390\/ijms262412020","article-title":"Peroxisome Proliferator-Activated Receptor \u03b1\/\u03b4\/\u03b3 Activation Profile by Endogenous Long-Chain Fatty Acids","volume":"26","author":"Honda","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2026.119432_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0118790","article-title":"Structure-based virtual screening and discovery of New PPAR\u03b4\/\u03b3 dual agonist and PPAR\u03b4 and \u03b3 agonists","volume":"10","author":"Maltarollo","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2026.119432_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113807","article-title":"Discovery of the first-in-class dual PPAR\u03b4\/\u03b3 partial agonist for the treatment of metabolic syndrome","volume":"225","author":"Li","year":"2021","journal-title":"Eur. J. Med. Chem."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226004683?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226004683?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:43:59Z","timestamp":1794476639000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226004683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":46,"alternative-id":["S0753332226004683"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119432","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination therapy with clinically approved PPAR\u03b1\/\u03b4\/\u03b3 subtype-selective agonists pemafibrate, seladelpar, and pioglitazone in a 4-week diet-induced early-stage MASLD mouse model","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119432","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119432"}}